3 OHSU researchers receive Biomedical Innovation Program awards

Pancreatic cancer,  prostate cancer, and SARS-CoV-2 — these are the targets of research projects funded by the 2020 Biomedical Innovation Program in the drug discovery track.

This category of funding supports drug discovery platforms and early-stage therapeutic technology projects, including validation of drug targets and development of small molecules, antibodies, vaccines, or biologics. The awards provide funds, project management and mentorship to support researchers moving innovative technologies from laboratories toward and into the clinic.

2020 Biomedical Innovation Program

Drug discovery track awardees and projects 

Pictured above: The Biomedical Innovation Funding program supported the development of Dr. Luiz Bertassoni’s “tooth-on-a-chip” device. (OHSU/Kristyna Wentz-Graff, 2019). Read about this device and its potential to transform dentistry.

Raymond C. Bergan, M.D., professor of medicine, School of Medicine, and associate director of medical oncology, OHSU Knight Cancer Institute, was awarded a grant for the development of dual-acting bone defending agents and expanded toxicology assessment.

Dexing Zeng Ph.D., associate professor of diagnostic radiology and director of organic chemistry at the Center for Radiochemistry Research, School of Medicine, received funding for the project ““Novel Albumin Binder Incorporated Peptide for αvβ6-targeted Pancreatic Cancer Radiotheranostics.”

John V. Brigande, Ph.D., associate professor of otolaryngology-head and neck surgery, and associate professor of cell, developmental and cancer biology in the School of Medicine, was awarded funding to generate a mouse model susceptible to SARS-CoV-2 infection by the genome editing technology i-GONAD.

The Oregon Clinical & Translational Research Institute, OHSU Collaborations & Entrepreneurship, and OHSU Technology Transfer jointly administer the program. Funding for the program is made possible by the University Venture Development Fund. Interested donors are encouraged to email Timothy Coffey.

OCTRI is supported by (UL1TR002369) from the National Center for Advancing Translational Science at the National Institutes of Health.